Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab

NCT06681298 is registered in ClinicalTrials.gov with xiaohua li as lead sponsor.

NCT NCT06681298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06681298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab
Lead sponsor
xiaohua li
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 1, 2024
Completion date
May 1, 2029
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the esophagogastric junction, perioperative period